Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
A WHO grade I meningioma characterized by the presence of epithelial differentiation and numerous intracellular PAS positive bodies that are rich in glycogen.
Biomarker and diagnostic research for secretory meningioma has been reported in the published literature.
62 clinical trials registered, 40 recruiting. Interventions under study include other interventions, drug therapy, procedural interventions, and medical devices. Pipeline includes 2 PHASE4, 12 PHASE2, 9 PHASE1. Research is sponsored by a mix of industry and academic institutions.
NCT ID | Title | Phase | Sponsor | Status |
|---|---|---|---|---|
[NCT04081701](https://clinicaltrials.gov/study/NCT04081701) |
Data assembled from 3 of 12 sources · Last updated Sep 20, 2026, 3:06 PM UTC
68-Ga DOTATATE PET/MRI in the Diagnosis and Management of Somatostatin Receptor Positive CNS Tumors. |
PHASE4 |
Weill Medical College of Cornell University |
RECRUITING |
[NCT05425004](https://clinicaltrials.gov/study/NCT05425004) | Cabozantinib for Patients With Recurrent or Progressive Meningioma | PHASE2 | Baptist Health South Florida | RECRUITING |
[NCT07493447](https://clinicaltrials.gov/study/NCT07493447) | Pilot Study Evaluating Panitumumab-IRDye800 as an Optical Imaging Agent to Detect Intracranial Lesions During Neurosurgical Procedures | EARLY_PHASE1 | Eben Rosenthal | RECRUITING |
[NCT05139277](https://clinicaltrials.gov/study/NCT05139277) | Evaluation of the CONVIVO System | NA | Dartmouth-Hitchcock Medical Center | RECRUITING |
[NCT04374305](https://clinicaltrials.gov/study/NCT04374305) | Innovative Trial for Understanding the Impact of Targeted Therapies in NF2-Related Schwannomatosis (INTUITT-NF2) | PHASE2 | Scott R. Plotkin, MD, PhD | RECRUITING |
166 publications have been identified in PubMed for secretory meningioma. Research spans Review / Meta-Analysis (30%), Basic Science / Preclinical (21%), and Diagnostic / Biomarker (13%).
Research Type | Count | % of Total |
|---|---|---|
Research summaries | 49 | 30% |
Laboratory research | 35 | 21% |
Testing and diagnosis research | 21 | 13% |
Disease patterns and progression | 19 | 11% |
Patient case studies | 17 | 10% |
Clinical study results | 11 | 7% |
New treatment approaches | 8 | 5% |
Other research | 6 | 4% |
Wei CZ (2026). [PMID: 40844288](https://pubmed.ncbi.nlm.nih.gov/40844288/). *Neurosurgery*. [Review / Meta-Analysis]
Aggarwal A (2026). [PMID: 41476144](https://pubmed.ncbi.nlm.nih.gov/41476144/). *Neuro Oncol*. [Basic Science / Preclinical]
Zhang L (2026). [PMID: 41642951](https://pubmed.ncbi.nlm.nih.gov/41642951/). *Adv Sci (Weinh)*. [Basic Science / Preclinical]
Ye E (2026). [PMID: 41526775](https://pubmed.ncbi.nlm.nih.gov/41526775/). *Childs Nerv Syst*. [Review / Meta-Analysis]
Juncà A (2026). [PMID: 41521239](https://pubmed.ncbi.nlm.nih.gov/41521239/). *Sci Rep*. [Basic Science / Preclinical]
Cheng X (2026). [PMID: 40836018](https://pubmed.ncbi.nlm.nih.gov/40836018/). *Eur Radiol*. [Diagnostic / Biomarker]
Simmons BT (2026). [PMID: 41941830](https://pubmed.ncbi.nlm.nih.gov/41941830/). *J Neurosurg Case Lessons*. [Case Report / Case Series]
Noriega-Silva LA (2026). [PMID: 41774884](https://pubmed.ncbi.nlm.nih.gov/41774884/). *Rev Med Inst Mex Seguro Soc*. [Case Report / Case Series]
Maier AD (2026). [PMID: 41486296](https://pubmed.ncbi.nlm.nih.gov/41486296/). *Acta Neuropathol Commun*. [Basic Science / Preclinical]
Tettamanti G (2026). [PMID: 41056434](https://pubmed.ncbi.nlm.nih.gov/41056434/). *Neuro Oncol*. [Epidemiology / Natural History]